| 1.22 0.02 (1.67%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.67 | 1-year : | 1.95 |
| Resists | First : | 1.42 | Second : | 1.67 |
| Pivot price | 1.15  |
|||
| Supports | First : | 1.07 |
Second : | 0.86 |
| MAs | MA(5) : | 1.19 |
MA(20) : | 1.1 |
| MA(100) : | 1.09  |
MA(250) : | 2.03 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.4 |
D(3) : | 54.2 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 5.53 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BLUE ] has closed below upper band by 35.9%. Bollinger Bands are 32.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.26 |
| Low: | 1.16 - 1.16 | 1.16 - 1.17 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Sat, 20 Jul 2024
bluebird bio, Inc. (NASDAQ:BLUE) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Tue, 16 Jul 2024
Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm - Victoria Advocate
Fri, 12 Jul 2024
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Wed, 15 May 2024
Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Sat, 11 May 2024
bluebird bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript - Seeking Alpha
Thu, 09 May 2024
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 193 (M) |
| Held by Insiders | 1.0885e+008 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 29,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3177e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -683.8 % |
| Return on Assets (ttm) | -15.1 % |
| Return on Equity (ttm) | -47.9 % |
| Qtrly Rev. Growth | 17 % |
| Gross Profit (p.s.) | 415.88 |
| Sales Per Share | 2.55647e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -277 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.49 |
| Dividend | 0 |
| Forward Dividend | 3.071e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|